Guided by our Medical & Scientific Advisory Panel (MSAP), Alzheimer’s Disease International’s position is that people making decisions about treatment benefit from information that is specific, balanced, and transparent. This includes an honest discussion of the potential advantages, the limitations, and the uncertainties of each approved therapy. Approaches that combine results from multiple drugs with very different characteristics can unintentionally obscure both signs of benefit and risks, precisely at a time when people affected by MCI (Mild Cognitive Impairment) or by dementia due to Alzheimer’s disease and carers are seeking practical guidance.

Read more HERE

• A 10-year study showed that APOE e4 carriers experience faster cognitive decline than APOE e2 and e3 carriers.
• Greater walking time appeared to benefit cognitive performance for female APOE e2 and e3 carriers.
• In males, walking time and APOE status were not as strongly associated with cognition.
• Maintaining walking time over 10 years was associated with slower cognitive decline among APOE e4 carriers.

Read more HERE

Long before the tell-tale signs of Parkinson’s disease appear, including tremors and muscle stiffness, there are other, more subtle signs of the disease.

These include changes in oral pronunciation and language and difficulties breathing or swallowing.

People with Alzheimer’s disease can also experience a reduction in their vocabulary and a tendency to repeat certain words. These also appear well before there is clear memory loss.

Read more HERE

Diagnoses of cognitive impairment and dementia should be based on symptoms and functional effects rather than biomarkers, argued a speaker at Internal Medicine Meeting 2026.

Read it all HERE

You may have heard that diabetes and Alzheimer’s disease are linked. This connection can sound concerning, especially if you are living with diabetes. But understanding what the research shows can help separate facts from myths, and help you focus on what supports long‑term health. Credentialled Diabetes Educator and Registered Nurse, Carolien Koreneff, explains.

Read it all HERE

Alzheimer’s research is entering a new phase, as treatments that have taken decades to develop begin to reach patients. But getting those advances to people will depend on more than scientific progress alone, according to pioneering Alzheimer’s researcher John Hardy.

Read more HERE